|
- Illumina | Sequencing and array solutions to fuel genomic discoveries
Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics
- Does Illumina’s 20% Surge Signal a Reversal After GRAIL Divestiture News?
News surrounding Illumina’s ongoing antitrust legal battles and recent strategic shifts, such as updates on the planned divestiture of GRAIL, have kept investors on edge These major headlines
- About Us | A global leader in genomics - Illumina
We are Illumina We are a global genomics and human health leader innovating the future of precision health We develop DNA sequencing and array-based life sciences technologies to enable boundless research discovery and personalized health
- Illumina, Inc. $ILMN Stake Lifted by Spyglass Capital . . . - MarketBeat
Key Points Spyglass Capital increased its Illumina stake by 25% to 698,565 shares (about $66 65M), making ILMN roughly 3 8% of Spyglass’s portfolio and its 11th-largest holding Institutional ownership is high at 89 42%, insiders own 2 60%, and director Scott Gottlieb recently bought 500 shares, raising his stake to 12,523 shares Illumina beat quarterly EPS estimates ($1 34 vs $1 16), set
- Statement Regarding Illumina’s Decision to Divest Grail
Illumina’s decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality tests for patients and physicians, ultimately saving lives
- Genomics products | Illumina
Illumina offers a broad range of sequencing and microarray products for diverse genomic analysis applications
- Twitter. It’s what’s happening Twitter
We would like to show you a description here but the site won’t allow us
- Press Releases | Stay on top of breaking Illumina news
Press Releases Press releases Stay on top of breaking news from Illumina Subscribe News Center:
|
|
|